Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis

Kidney International, Supplement

Volumn 67, Issue 95, 2005, Pages

  Nolan, Charles R ^a   Qunibi, Wajeh Y ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Calcium acetate; Cardiovascular calcification; Hypercalcemia; Metabolic acidosis; Phosphate binders; Sevelamer hydrochloride

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; ACETIC ACID DERIVATIVE; EPOXIDE; PHOSPHATE; POLYAMINE; POLYETHYLENE DERIVATIVE; CALCIUM BASED PHOSPHATE BINDER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ALUMINUM OVERLOAD; BLOOD VESSEL CALCIFICATION; BRAIN DISEASE; CALCIUM BALANCE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MAINTENANCE THERAPY; OSTEOMALACIA; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT; ACID BASE BALANCE; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; CORONARY BLOOD VESSEL; DISEASE COURSE; ECONOMICS; PATHOLOGY; RENAL REPLACEMENT THERAPY; UNITED STATES; BONE METABOLISM; DIET RESTRICTION; DRUG EFFECT; HYPERPARATHYROIDISM; MORTALITY;

ACETATES; ACID-BASE EQUILIBRIUM; CALCINOSIS; CORONARY VESSELS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS; UNITED STATES;

EID: 24944541616     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09502.x     Document Type: Article

References (34)

1. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
2. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
3. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S202, 2003
4. SILVER J: Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv Renal Replacement Ther 9:159-167, 2002
5. SILVER J, KILAV R, NAVEH-MANY T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Fluid Electrolyte Physiology 283:F367-F376, 2002
6. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidny Dis 35(Suppl 2):S1-S140, 2000
7. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
8. BLEYER AJ, BURKE SK, DILLON M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
9. SLATOPOLSKY EA, BURKE SK, DILLON MA, et al: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299-307, 1999
10. GOLDBERG DI, DILLON MA, SLATOPOLSKY EA, et al: Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13:2303-2310, 1998
11. CHERTOW GM, BURKE SK, RAGGI P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
12. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE study). Kidney Int 65:1914-1926, 2004
13. MANN B, STEVENS L, MISKULIN D, et al: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239-1247, 2004
14. LOWRIE EG, LEW NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990.
15. FOLEY RN, PARFREY PS, HARNETT JD, et al: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16:386-393, 1996
16. CHERTOW GM, DILLON GM, BURKE SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999
17. QUNIBI WY, NOLAN CR, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int 62(Suppl 82):S73-S80, 2002
18. DAVIES MR, LUND RJ, HRUSKA KA: BMP-7 is an efficacious treatment of vascular calcification in murine models of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14:1559-1567, 2003
19. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
20. GUÉRIN AP, LONDON GM, MARCHAIS SJ, et al: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
21. CHERTOW GM, RAGGI P, CHASAN-TABER, et al: Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant 19:1489-1496, 2004
22. SHEIKH MS, MAGUIRE JA, EMMETT M, et al: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro and in vivo study. J Clin Invest 83:66-73, 1989
23. SHEIKH MS, SANTA ANA CA, NICAR MJ, et al: Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 317:532-536, 1987
24. CHERTOW GM, RAGGI P, MCCARTHY JT, et al: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23:307-314, 2003
25. HOU SH, ZHOA J, ELLMAN CF, et al: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217-224, 1991
26. CALLISTER TQ, RAGGI P, COOIL B, et al: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339:1972-1978, 1998
27. ACHENBACH S, ROPERS D, POHLE K, et al: Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation 106:1077-1082, 2002
28. NITTA K, AKIBA T, NIHEI H: Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in hemodialysis patients. Nephrol Dial Transplant 19:2156, 2004
29. Drug Topic 2003 Redbook, Montvale, NJ, Thomson PDR, 2003
30. BUSHINSKY DA: Net calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol 256:F836-842, 1998
31. BUSHINSKY DA, FRICK KK: The effects of acid on bone. Curr Opin Nephrol Hypertens 9:369-379, 2000
32. BUSHINSKY DA, NILSSON EL: Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Am J Physiol 269:C1364-1370, 1995
33. BAILEY JL, WANG X, ENGLAND BK, et al: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453, 1996
34. BALLMER PE, MCNURLAN MA, HULTER HN, et al: Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95:39-45, 1995